MEDI 8111

Drug Profile

MEDI 8111

Alternative Names: Rh-Factor II; rhFII

Latest Information Update: 07 Oct 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator MedImmune
  • Class Antithrombotics; Enzyme precursors
  • Mechanism of Action Blood coagulation factor replacements; Prothrombin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Haemorrhage

Most Recent Events

  • 01 Oct 2014 AstraZeneca (MedImmune) completes a phase I trial in Haemorrhage (In volunteers) in United Kingdom (NCT01958645)
  • 22 Nov 2013 Phase-I clinical trials in Haemorrhage (In volunteers) in United Kingdom (IV)
  • 07 Oct 2013 Preclinical trials in Haemorrhage in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top